Celera, Wisconsin provider collaborate on cardiovascular gene testing
Aurora Health Care and healthcare gentics company Celera have entered into an agreement to collaborate on the integration of genetic testing to optimize heart care at Aurora.

Under the agreement, Milwaukee-based Aurora will offer patients a test for a variant in a gene called KIF6, which studies have shown indicates a significantly increased risk for heart disease. This testing, which will be Aurora's first use of genetic testing in cardiovascular care, is expected to start with patients of Aurora's Cardiovascular Services.

Aurora and the Alameda, Calif.-based Celera also have agreed to explore research areas of mutual interest to validate additional genetic markers for cardiovascular disease risk and treatment.